Published in Mol Ther on October 19, 2010
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol (2012) 1.90
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol (2012) 1.11
Biomaterials for nanoparticle vaccine delivery systems. Pharm Res (2014) 1.09
Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release (2013) 1.02
Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol (2012) 1.00
Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res (2012) 0.92
Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. PLoS One (2013) 0.88
Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. J Virol (2014) 0.86
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep (2014) 0.86
Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin. PLoS One (2015) 0.83
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines (Basel) (2013) 0.82
Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res (2014) 0.82
Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J Control Release (2013) 0.81
Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol (2011) 0.79
Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics (2014) 0.78
Regulatory T-cell development and function are impaired in mice lacking membrane expression of full length intercellular adhesion molecule-1. Immunology (2015) 0.76
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75
Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. Oncoimmunology (2016) 0.75
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. Front Immunol (2017) 0.75
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol (1987) 5.30
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med (2007) 3.57
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Induction of secretory immunity and memory at mucosal surfaces. Vaccine (2006) 2.24
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis (2004) 1.84
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol (2008) 1.70
Rapid-response vaccines--does DNA offer a solution? Nat Biotechnol (2005) 1.67
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine (2000) 1.63
A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A (2008) 1.59
Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther (2007) 1.52
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol (1999) 1.13
Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg Infect Dis (2010) 1.07
Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol (2004) 1.05
Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One (2008) 1.04
Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine (1990) 1.00
Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine (2003) 0.99
Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther (2008) 0.99
The road to licensure of a DNA vaccine. Curr Opin Investig Drugs (2007) 0.97
A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis (2009) 0.97
Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine (2004) 0.96
Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes (2008) 0.96
Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine (2003) 0.96
Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther (2000) 0.94
Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol (2010) 0.91
Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine (2006) 0.90
DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine (2009) 0.90
Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis (1999) 0.90
PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine (2009) 0.89
PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther (2003) 0.87
Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine (2003) 0.86
Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine (2009) 0.85
Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine (2008) 0.85
Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken. Vaccine (2009) 0.82
Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev Vaccines (2007) 0.79
A universal avian endogenous real-time reverse transcriptase-polymerase chain reaction control and its application to avian influenza diagnosis and quantification. Avian Dis (2007) 0.78
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med (2003) 4.39
Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med (2002) 3.70
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest (2003) 2.85
Highly pathogenic H5N1 influenza virus in smuggled Thai eagles, Belgium. Emerg Infect Dis (2005) 2.37
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med (2008) 2.01
Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol (2011) 1.94
Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood (2008) 1.94
Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur J Immunol (2006) 1.52
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood (2003) 1.41
Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum (2011) 1.38
CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. Immunol Lett (2005) 1.25
A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med (2011) 1.23
Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood (2005) 1.21
Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol (2006) 1.20
Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol (2012) 1.19
Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J (2006) 1.19
High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. Eur J Immunol (2009) 1.19
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest (2009) 1.17
Comprehensive assessment and mathematical modeling of T cell population dynamics and homeostasis. J Immunol (2008) 1.15
Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol (2007) 1.11
Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol (2006) 1.10
Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood (2003) 1.10
A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain (2012) 1.08
CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med (2010) 1.08
Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg Infect Dis (2010) 1.07
Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol (2011) 1.06
Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood (2010) 1.04
Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther (2012) 1.02
Human CD90 identifies Th17/Tc17 T cell subsets that are depleted in HIV-infected patients. J Immunol (2011) 1.02
Influenza vaccines and vaccination strategies in birds. Comp Immunol Microbiol Infect Dis (2007) 1.02
Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther (2004) 1.01
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol (2009) 1.00
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus (2006) 0.99
Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther (2003) 0.99
Induction of antigen-specific tolerance by intrathymic injection of lentiviral vectors. Blood (2006) 0.98
Infectious Bursal Disease: a complex host-pathogen interaction. Dev Comp Immunol (2013) 0.97
DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine (2005) 0.97
Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther (2005) 0.96
Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters. J Gene Med (2005) 0.96
Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol (2009) 0.95
In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest (2005) 0.92
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology (2013) 0.91
The proatherogenic role of T cells requires cell division and is dependent on the stage of the disease. Arterioscler Thromb Vasc Biol (2005) 0.91
Phylogeographic analysis of avian influenza viruses isolated from Charadriiformes in Belgium confirms intercontinental reassortment in gulls. Arch Virol (2012) 0.91
Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther (2007) 0.91
Turning immunological memory into amnesia by depletion of dividing T cells. Proc Natl Acad Sci U S A (2003) 0.90
DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine (2009) 0.90
Enveloped virus-like particle platforms: vaccines of the future? Expert Rev Vaccines (2015) 0.89
Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood (2002) 0.89
Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int J Oncol (2002) 0.88
Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood stem cell-based gene therapy. AIDS (2003) 0.88
State-transition diagrams for biologists. PLoS One (2012) 0.87
Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol (2004) 0.87
GFP-transduced CD34+ and Lin- CD34- hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct. Exp Hematol (2007) 0.87
Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain (2006) 0.87
Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood (2005) 0.87
In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors. BMC Immunol (2004) 0.86
Further evidence for the widespread co-circulation of lineages 4b and 7 velogenic Newcastle disease viruses in rural Nigeria. Avian Pathol (2012) 0.85
IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment. AIDS (2009) 0.85
Beneficial role of rapamycin in experimental autoimmune myositis. PLoS One (2013) 0.85
Self-specific memory regulatory T cells protect embryos at implantation in mice. J Immunol (2013) 0.85
Autochthonous tick-borne encephalitis virus-seropositive cattle in Belgium: a risk-based targeted serological survey. Vector Borne Zoonotic Dis (2014) 0.85
Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine (2012) 0.84
Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep (2014) 0.84
Early detection of a two-long-terminal-repeat junction molecule in the cytoplasm of recombinant murine leukemia virus-infected cells. J Virol (2004) 0.84
Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line. J Gene Med (2004) 0.84
Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J Clin Invest (2016) 0.83
GeVaDSs - decision support system for novel Genetic Vaccine development process. BMC Bioinformatics (2012) 0.83
Experimental infection of Carrion crows (Corvus corone) with two European West Nile virus (WNV) strains. Vet Microbiol (2013) 0.83
Adjuvant interleukin-12 gene therapy for the management of colorectal liver metastases. Cancer Gene Ther (2004) 0.82
Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med (2009) 0.82
Accelerated Achilles tendon healing by PDGF gene delivery with mesoporous silica nanoparticles. Biomaterials (2010) 0.82
Vaccination of chicken embryos with escape mutants of La Sota Newcastle disease virus induces a protective immune response. Vaccine (2005) 0.82
Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum Gene Ther (2013) 0.82
Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol (2013) 0.82
Humoral, cell-mediated and mucosal immunity induced by oculo-nasal vaccination of one-day-old SPF and conventional layer chicks with two different live Newcastle disease vaccines. Vaccine (2009) 0.82
Systems biology in vaccine design. Microb Biotechnol (2011) 0.82
Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J Immunol (2006) 0.81
Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum (2008) 0.81
A novel strategy for molecular signature discovery based on independent component analysis. Int J Data Min Bioinform (2014) 0.81
Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol (2011) 0.81
What's in a strain? Viral metagenomics identifies genetic variation and contaminating circoviruses in laboratory isolates of pigeon paramyxovirus type 1. Virus Res (2012) 0.81
Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol (2004) 0.80